OIPE
OCT 20 2003
PATENT & TRADEMARK OFFICE

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Powers et al.

Serial No.: 10/671,360

Filed: September 25, 2003

Confirmation No.: N/A

Group Art Unit: Unknown

Examiner: Unknown

Docket No.: 820701-1015

For: KETOAMIDE INHIBITORS IN CHRONIC NERVE DISEASE

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

This information disclosure statement is filed in accordance with 37 C.F.R. §§ 1.56, 1.97, and 1.98, and specifically:

☒ under 37 CFR 1.97(b), or
(within Three months of filing national application; or date of entry of international application; or before mailing date of first office action on the merits; whichever occurs last)

☐ under 37 CFR 1.97(c) together with either a:
- ☐ Statement Under 37 C.F.R. 1.97(e), or
- ☐ a $180.00 fee under 37 CFR 1.17(p), or

(After the CFR 1.97(b) time period, but before the final office action or notice of allowance, whichever occurs first)

☐ under 37 CFR 1.97(d) together with a:
- ☐ Statement under 37 CFR 1.97(e), and
- ☐ a $180.00 petition fee set forth in 37 CFR 1.17(p).

(Filed after final office action or notice of allowance, whichever occurs first, but before payment of the issue fee)

Enclosed is a check in the amount of $. Please charge $ to deposit account . At any time during the pendency of this application, please charge any fees required to Deposit Account pursuant to 37 CFR 1.25. The Commissioner is hereby requested to credit any overpayment to Deposit Account No. .

☒ Applicant(s) submit herewith *Form PTO 1449A - Information Disclosure Statement by Applicant* together with copies of publications or other information of which applicant(s) are aware, which applicant(s) believe(s) may or may not be material to the examination of this application and for which there may be a duty to disclose in accordance with 37 CFR 1.56. As required by 37 C.F.R. §1.98(a), a legible copy of each document is provided.

☐ A concise explanation of the relevance of foreign language patents, foreign language publications and other foreign language information listed on PTO Form 1449, as presently understood by the individual(s) designated in 37 CFR 1.56(c) most knowledgeable about the content is given on the attached sheet, or where a foreign language patent is cited in a search report or other action by a foreign patent office in a counterpart foreign application, an English language version of the search report or action which indicates the degree of relevance found by the foreign office is listed on the form PTO 1449 and is enclosed herewith.

The following rights are reserved by the Applicant(s): the right to establish the patentability of the claimed invention over any of the listed documents should they be applied as reference, and/or the right to prove that some of these documents may not be prior art, and/or the right to prove that some of these documents may not be enabling for the teachings they purport to offer.

This statement should not be construed as a representation that an exhaustive search has been made, or that information more material to the examination of the present application does not exist. Any statements or identifications regarding the relevance of any portion(s) of cited references should not be construed as a representation that the most relevant portion(s) have been identified, and the absence of such statements or identifications should not be construed as representations that there are no relevant portion(s). The Examiner is specifically requested not to rely solely on the materials submitted herewith. The Examiner is requested to conduct an independent and thorough review of the documents, and to form independent opinions as to their significance.

It is requested that the information disclosed herein be made of record in this application and that the Examiner initial and return a copy of the enclosed PTO-1449 to indicate the documents have been considered.

Respectfully Submitted,

THOMAS, KAYDEN, HORSTEMEYER & RISLEY, L.L.P.

By: _____

Charles Vorndran, Reg. No. 45,315

100 Galleria Parkway, Suite 1750
Atlanta, Georgia 30339-5948
770-933-9500

CERTIFIED MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as **"First Class Mail,"** in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 10-17-03

Signature

OIPE JC119 OCT 20 2003 PATENT & TRADEMARK OFFICE

Form PTO-1449

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

Attorney Docket No.	Serial No.
820701-1015	**10/671,360**
Applicant: **Powers et al.**	
Filing Date: **September 25, 2003**	Group: **Unknown**

U.S. PATENT DOCUMENTS

Examiner Initials	Item	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
/CB/	A	5,514,694	5/97	Powers et al.	514	357	6/93
/CB/	B	5,610,297	3/97	Powers	544	168	10/95
/CB/	C	5,650,508	7/97	Powers	544	168	10/95
/CB/	D	6,235,929	5/01	Powers	562	450	12/96

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, etc.)*

/CB/	1	Dourdin et al. *Reduced Cell Migration and Disruption of the Actin Cytoskeleton in Calpain-deficient Embryonic Fibroblasts.* The Journal of Biological Chemistry, December 21, 2001, Vol. 276, No. 51, pp. 48382-48388.
/CB/	2	Kohli et al. *Calpain is a mediator of preservation-reperfusion injury in rat liver transplantation.* Proc. Natl. Acad. Sci. USA, Medical Sciences, August 1997, Vol. 94, pp. 9354-9359.
/CB/	3	Kupina et al. *The Novel Calpain Inhibitor SJA6017 Improves Functional Outcome after Delayed Administration in a Mouse Model of Diffuse Brain Injury.* Journal of Neurotrauma, 2001, Vol. 18, No. 11, pp. 1229-1240.
/CB/	4	Markgraf et al. *Six-hour Window of Opportunity for Calpain Inhibition in Focal Cerebral Ischemia in Rats.* American Heart Association, Inc., 1998, pp. 152-158.
/CB/	5	Saatman et al., *Calpain inhibitor AK295 attenuates motor and cognitive deficits following experimental brain injury in the rat.* Proc. Natl. Acad. Sci. USA, Neurobiology, April 1996, Vol. 93, pp. 3428-3433.
/CB/	6	Schumacher et al. *Pretreatment with Calpain Inhibitor CEP-4143 Inhibits Calpain I Activiation and Cytoskeletal Degradation, Improves Neurological Function, and Enhances Axonal Survival After Traumatic Spinal Cord Injury.* Journal of Neurochemistry, ~~200~~ 2000, Vol. 74, No. 4, pp.1646-1655. /CB/
/CB/	7	Shields et al. *A punative mechanism of demyelination in multiple sclerosis by a proteolytic enzyme, calpain.* Proc. Natl. Acad. Sci. USA, September 1999, Vol. 96, pp. 11486-11491.

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.

EXAMINER'S SIGNATURE: /Christina Bradley/ (04/17/2008)	DATE CONSIDERED: